Evidence map›Paper›PMID 40337706›Full record

ArticleIranian journal of microbiology2025

Onychomycosis among cancer patients undergoing chemotherapy in Tehran, Iran: a cross-sectional study.

Fatemeh Fathi, Farhad Shahi, Alireza Khosravi, Zahra Saffarian, Nader Safarian, Mir Saeed Yekaninejad, Zoha Shaka

Abstract read
In one paragraph

Article in Iranian journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatemeh FathiDepartment of Dermatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Farhad ShahiBreast Disease Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Alireza KhosraviDepartment of Microbiology and Immunology, School of Veterinary Medicine, Tehran University, Tehran, Iran.
Zahra SaffarianDepartment of Dermatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Nader SafarianHaemostasis and Thrombosis Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mir Saeed YekaninejadDepartment of Epidemiology, School of Public Heath, Tehran University of Medical Sciences, Tehran, Iran.
Zoha ShakaCancer Research Center, Cancer Institute, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: Due to the persistence of residual fungal elements, onychomycosis tends to have a high recurrence rate. It is essential to determine the etiology and frequency of onychomycosis across various factors. This study aimed to assess the prevalence of onychomycosis and identify its fungal agents in cancer patients undergoing chemotherapy. Materials and Methods: This cross-sectional study was conducted on cancer patients attending the Oncology Clinic and Cancer Institute of Tehran University of Medical Sciences. Among the 165 patients meeting the inclusion criteria, 75 individuals with nail alterations were referred to a dermatologist. Each patient's information, including demographics, disease-related data, and details about nail involvement, was recorded. When onychomycosis was suspected, nail samples were collected from the deepest part and examined using a light microscope after clarifying with 15% potassium hydroxide (KOH) to detect fungal elements. Results: The prevalence of onychomycosis was 37.6% (n=62). Among the 75 patients with nail alterations and suspected onychomycosis, 17.3% (n=13) tested negative for pathogenic agents. The most common pathogen was Conclusion: Onychomycosis exhibits associations with variables such as gender, age, cancer and chemotherapy.

Indexed as

CancerChemotherapyOnychomycosis

Identifiers

PMID40337706
PMCPMC12053418

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.